ENDP : Analysis & Opinions

  1. FDA Approves Actavis Generic - Analyst Blog

    July 15, 2013
    Actavis is yet to fix its launch plans for the newly approved dosage strengths.
  2. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  3. Stock Market News for January 8, 2013 - Market News

    January 8, 2013
    Investor apprehensions surrounding fourth-quarter earnings dragged benchmarks into negative territory on Monday. Indices ...
  4. Patent Challenge for Auxilium Pharma - Analyst Blog

    January 7, 2013
    Auxilium Pharmaceuticals, Inc. (AUXL) and Xstelos Holdings, Inc. (XTLS) recently received a notice from Upsher-Smith Laboratories, ...
  5. Regeneron Pharmaceuticals Among Healthcare's Biggest Movers on ...

    November 15, 2012
    The market is currently down, with the Nasdaq falling 0.4%, the S&P 500 decreasing 0.3% and the Dow declining 0.3%. The healthcare ...
  6. Stock Market News for November 13, 2012 - Market News

    November 13, 2012
    Apprehension about this week's "fiscal cliff" discussion between top U.S. leaders and President Barack Obama led to benchmarks ...
  7. Healthcare Stocks, Including BioMarin Pharmaceutical, Making ...

    November 5, 2012
    The Nasdaq has moved up 0.1%, the S&P 500 has declined 0.3% and the Dow has slipped 0.3% so far today. The healthcare sector ...
  8. Endo Pharmaceuticals Holdings Inc and More Big Movers in Healthcare ...

    August 9, 2012
    The market is having a bad day so far. The Nasdaq is trading down 0.1%; the S&P 500 has decreased 0.2%; and the Dow has slipped ...
  9. The Salix Story Keeps Improving

    January 18, 2012
    Salix is a great candidate for growth investors.
  10. Valeant Offers A Princely Sum For Cephalon

    March 31, 2011
    Valeant offers a rare win-win bid for Cephalon.
  11. Salix Proves There Is Still Growth In Pharma

    March 3, 2011
    Salix has taken another blow from the FDA, but seems too cheap given its prospects.
  12. 5 Low-P/E Bargains Worth A Look

    June 14, 2010
    Averaged out across an entire portfolio, a basket of low P/E stocks has a good chance to outperform the overall market.
  13. A Rocky Week For Abbott Labs

    July 3, 2009
    This healthcare company has seen better weeks, but it's still too early to tell if recent bad news will pummel the stock.
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center